BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, Jamnani FR, Fateh A, Siadat SD. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol 2017;162:181-9. [DOI: 10.1007/s00705-016-3095-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Ghanem SE, Elsabaawy M, Shebl N, Abdelsameea E, Othman W, El-Bassal FI, Elgedawy GA, Elsabaawy DM, Helal ML. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther 2020;18:947-54. [PMID: 32419526 DOI: 10.1080/14787210.2020.1771180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 El-garawani I, Hassab El-nabi S, Gadallah M, Abdelsameea E. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients. Immunological Investigations 2021;50:12-22. [DOI: 10.1080/08820139.2020.1722158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Sadeghi S, Davari M, Asli E, Gharibzadeh S, Vaziri F, Jamnani FR, Fateh A, Siadat SD. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin. Gene 2017;630:28-34. [PMID: 28827115 DOI: 10.1016/j.gene.2017.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Abdel-raheem EM, Mosallem FA, Abdel Raheem MM, Mohamed A, Malek MG. Screening for hepatitis C virus infection among Minia city school students. Egyptian Pediatric Association Gazette 2018;66:66-70. [DOI: 10.1016/j.epag.2018.07.001] [Reference Citation Analysis]
5 Egli A, Mandal J, Schumann DM, Roth M, Thomas B, Lorne Tyrrell D, Blasi F, Kostikas K, Boersma W, Milenkovic B, Lacoma A, Rentsch K, Rohde GGU, Louis R, Aerts JG, Welte T, Torres A, Tamm M, Stolz D. IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes. BMC Pulm Med 2018;18:51. [PMID: 29562888 DOI: 10.1186/s12890-018-0616-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mobasheri S, Irani N, Sepahi AA, Sakhaee F, Jamnani FR, Vaziri F, Siadat SD, Fateh A. Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection. Gene 2018;676:95-100. [PMID: 30017737 DOI: 10.1016/j.gene.2018.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, Siadat SD. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 2017;18:144-51. [DOI: 10.1038/gene.2017.12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nafari M, Irani S, Vaziri F, Gharibzadeh S, Sakhaee F, Khazeni M, Kalhor N, Jamnani FR, Siadat SD, Fateh A. Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1. Infect Genet Evol 2018;62:296-303. [PMID: 29715527 DOI: 10.1016/j.meegid.2018.04.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bokharaei-salim F, Salehi-vaziri M, Sadeghi F, Khanaliha K, Esghaei M, Monavari SH, Alavian SM, Fakhim S, Keyvani H. Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection. Jundishapur J Microbiol 2016;10. [DOI: 10.5812/jjm.39178] [Reference Citation Analysis]
10 Yao Y, Liu M, Zang F, Yue M, Xia X, Feng Y, Fan H, Zhang Y, Huang P, Yu R. Association between human leucocyte antigen-DO polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study. BMJ Open 2018;8:e019406. [PMID: 29654010 DOI: 10.1136/bmjopen-2017-019406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Rahimi P, Tarharoudi R, Rahimpour A, Mosayebi Amroabadi J, Ahmadi I, Anvari E, Siadat SD, Aghasadeghi M, Fateh A. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J 2021;18:221. [PMID: 34775984 DOI: 10.1186/s12985-021-01692-z] [Reference Citation Analysis]